Patents by Inventor Shabber MOHAMMED

Shabber MOHAMMED has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO
    Publication number: 20220162186
    Abstract: The disclosure relates to Prostnglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 26, 2022
    Inventors: Thota GANESH, Raymond J. DINGLEDINE, Radhika AMARADAHI, Shabber MOHAMMED
  • 20-HETE FORMATION INHIBITORS
    Publication number: 20220144797
    Abstract: This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.
    Type: Application
    Filed: February 7, 2020
    Publication date: May 12, 2022
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Lee Apostle McDermott, David Koes, Samuel M. Poloyac, Shabber Mohammed
  • Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
    Patent number: 10696688
    Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 30, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Sandip Bibishan Bharate, Shashi Bhushan, Shabber Mohammed, Santosh Kumar Guru, Sonali Sandip Bharate, Vikas Kumar, Girish Mahajan, Mubashir Javed Mintoo, Dilip Manikrao Mondhe, Ram Vishwakarma
  • FUSED PYRIMIDINES AS ISOFORM SELECTIVE PHOSPHOINOSITIDE-3-KINASE-ALPHA INHIBITORS AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20200031845
    Abstract: The present invention relates to fused pyrimidines of formulae I and II wherein, R1, R2 are as herein described. The present invention particularly relates to isoform selective PI3K? inhibition and their medicinal use as anticancer agents.
    Type: Application
    Filed: November 21, 2016
    Publication date: January 30, 2020
    Inventors: Sandip Bibishan BHARATE, Shashi BHUSHAN, Shabber MOHAMMED, Santosh Kumar GURU, Sonali Sandip BHARATE, Vikas KUMAR, Girish MAHAJAN, Mubashir Javed MINTOO, Dilip Manikrao MONDHE, Ram VISHWAKARMA